UNH Stock: Undervalued or Overpriced After 66.6% Gain?

UnitedHealth Group's stock has seen a significant 66.6% gain over the past year, but its valuation and current pricing still leave room for debate.

The company's diversified health insurance and services model supports expectations for steady cash generation, while ongoing regulatory and reimbursement risk may limit investor willingness to pay.

A market multiple view suggests UnitedHealth Group is undervalued, with a value score of 4 out of 6 indicating a mixed picture rather than a clear bargain or overvaluation.

The stock's P/E ratio sits at around 26.2x, slightly above the healthcare industry average but below its peer group average, and well below its fair value of 40.2x based on earnings profile.